Akcea Therapeutics
As of the edition of 20 October 2026, Akcea Therapeutics runs 45 drugs, 8 of them marketed; it is on route A at 8 targets and on route B at 1 target.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Akcea Therapeutics was renamed in 2015.
The records place 3 company names in this family.
- IONIS PHARMACEUTICALS INC: renamed in 2015
- Akcea Therapeutics: acquired in 2020; successor IONIS PHARMACEUTICALS INC
Drugs by status
| Status | Count |
|---|---|
| Marketed | 8 |
| Active | 12 |
| Went quiet | 11 |
| Stopped | 6 |
| Status not established | 8 |
| Total | 45 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Olezarsen | none listed | 1 |
| Eplontersen | none listed | 2 |
| Donidalorsen | none listed | 0 |
| Volanesorsen | none listed | 0 |
| Inotersen | Ends 2031 (patent) | 1 |
| Zilganersen | none listed | 0 |
| Donidalorsen sodium | Ends 2035 (patent) | 0 |
| Olezarsen sodium | Ends 2034 (patent) | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 8 targets, route B at 1 target.
All 9 rows on route A or B
In the product9 company-target rows on route A or B; 6 are not shown here, and no score is.
See all 9 targets where Akcea Therapeutics needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Nutrition and metabolism: 36 trials led
- Inherited and neonatal: 30 trials led
- Heart and blood vessels: 21 trials led